Immune Checkpoint Inhibitor-related Adverse Events Guideline V1

SITC's Immune-Checkpoint Inhibitor-Related Adverse Events Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.